This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Post-marketing Surveillance Study of A.M.I. Protector Adjustable Gastric Band

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Weight to Go Ltd.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Weight to Go Ltd Identifier:
First received: December 11, 2012
Last updated: December 18, 2012
Last verified: December 2012
The laparoscopic adjustable gastric band (LAGB) is a safe and effective surgical intervention for chronically obese patients who have exhausted all non-surgical weight loss treatments. Numerous published studies have confirmed both the safety and efficacy of the LAGB and its beneficial impact on obesity-associated conditions, such as type 2 diabetes, joint and back pain and hypertension. The A.M.I. Protector Band is a modification of an existing gastric band (the A.M.I. Soft Gastric Band) which has been in use since 2001 and which has been shown to be both safe and effective. The specific design modification is in the form of a section of mesh, which provides support to the gastric pouch and which further restricts food portion sizes. The expectation is that this will deliver optimal weight loss whilst having the maximum possible impact on obesity-associated conditions such as type 2 diabetes and hypertension. In the longer term, there is also the possibility that the Protector Band will reduce the incidence of band complications such as slippage and dilatation (or stretching) of the gastric pouch. In this study we will recruit approximately 200 patients who will then undergo surgical implantation of the A.M.I. Protector Band. The study participants will then be followed for a period of 3-years, during which time we will record weight loss, changes in co-morbid conditions such as diabetes and the incidence of band complications, including slippage and pouch dilatation.


Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: A Single-arm, Observational, Post-marketing Study to Evaluate the Effects of the A.M.I. Protector Adjustable Gastric Band on Weight Loss, Co-morbidities, Adverse Events and Other Clinical Characteristics.

Resource links provided by NLM:

Further study details as provided by Weight to Go Ltd:

Primary Outcome Measures:
  • Percentage excess weight loss (%EWL) [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Impact of weight loss on co-morbidities such as type 2 diabetes, hypertension etc [ Time Frame: 3-years ]
  • Incidence of band-related complications such as band slippage; erosion; port/tubing complications; port/band infection; pouch dilatation [ Time Frame: 3 years ]

Estimated Enrollment: 200
Study Start Date: January 2013
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Detailed Description:

Where patients express an interest in the A.M.I. Protector Band, they will be given a Patient Information Sheet which will form the basis of a discussion with the attending physician. Patients opting for the Protector Band will be told that their anonymised clinical data will be stored in a secure database and used for research purposes. They will also be required to attend for regular follow-up (see below) for a period of three years after implantation.

Following this initial consultation, a minimum period of 2-weeks will be required before the patient is listed for surgery. This will provide a suitable period during which the patient can consider the options and seek clarification on any points about which they are unclear.

In the case of the A.M.I. Protector Band the surgery will be performed in two locations:

  • Spire Hospital Parkway (Birmingham)
  • Spire Hospital Manchester

All band procedures will be performed by one of two surgeons; Mr. Paul Super and Prof. Franco Favretti according to a standard protocol.

In all cases, informed consent will be obtained prior to surgery.

Patients will remain in hospital overnight and be discharged the following day.

On discharge, patients will be given comprehensive written instructions regarding optimal nutritional and physical activity. They will also be provided with a 24-hour, Emergency Helpline number in the event of problems.

All patients will be followed for a period of three years, with a formal review at 5 weeks and then at 3, 6, 9, 12, 18, 24 and 36 months. However, patients will be free to attend additional clinics between the formal reviews should they wish. At each visit the patient's weight, height, waist/hip ratio and blood pressure (BP) will be recorded. In addition, a range of blood tests will be carried out at baseline, at 12, 24 and 36 months. A self-administered Quality of Life questionnaire will be completed prior to surgery and then at 12, 24 and 36 months of follow-up.

At the completion of the 3-year study, patients will be able to transition into our usual care gastric band programme for long-term follow-up.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Obese subjects who are candidates for gastric banding

Inclusion Criteria:

  • obese subjects with BMI >30kg/m2 with one or more co-morbidities
  • Obese subjects with BMI >40kg/m2 with or without co-morbidities

Exclusion Criteria:

  • previous history of drug abuse
  • history of bleeding disorders
  • On long-term steroid therapy
  • Pregnancy
  • Previous gastric surgery
  • Chronic lung disease
  • history of psychotic disease
  • Inflammatory bowel disease
  • Unstable angina or dysrhythmia
  • liver cirrhosis
  • Autoimmune disease (SLE etc)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01752829

Contact: Dr David Ashton, MD PhD 07899913963

United Kingdom
Weight To Go Ltd Not yet recruiting
Birmingham, United Kingdom, B15 3ES
Contact: Dr David Ashton, MD PhD    07899913963   
Contact: Chrissie Twigg, MA, MBA    07867506195   
Principal Investigator: Dr David Ashton, MD, PhD         
Sponsors and Collaborators
Weight to Go Ltd
Principal Investigator: Dr David Ashton, MD PhD Weight to Go Ltd
  More Information

Responsible Party: Weight to Go Ltd Identifier: NCT01752829     History of Changes
Other Study ID Numbers: Version PBS.V2.11.12
Study First Received: December 11, 2012
Last Updated: December 18, 2012

Keywords provided by Weight to Go Ltd:
Excess weight loss
adjustable gastric banding processed this record on September 19, 2017